Fenwick & West and Goodwin Procter represented Royalty Pharma plc in the transaction, and Latham & Watkins and Mazanti-Andersen represented Ascendis Pharma A/S.Ascendis Pharma A/S (Nasdaq:…
Royalty Pharma’s $150 Million Royalty Funding Agreement with Ascendis Pharma
